期刊
NATURE REVIEWS NEUROLOGY
卷 16, 期 2, 页码 63-64出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/s41582-019-0295-9
关键词
-
资金
- Medical Research Council [MR/S021418/1] Funding Source: Medline
Trials of aducanumab in Alzheimer disease were previously discontinued following a phase III futility analysis, but Biogen now says that additional data indicate that longer exposure to the higher dose might be effective. The company is seeking FDA approval for the treatment; however, the limited data released do not establish efficacy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据